Comments on: Here we go again–Lilly’s Alzheimer’s drug solanezumab fails to show efficacy in Phase 3, but company is “encouraged” by secondary analysis

Comments on: Here we go again–Lilly’s Alzheimer’s drug solanezumab fails to show efficacy in Phase 3, but company is “encouraged” by secondary analysis https://biopharmconsortium.com/2012/08/29/here-we-go-again-lillys-alzheimers-drug-solanezumab-fails-to-show-efficacy-in-phase-3-but-company-is-encouraged-by-secondary-analysis/#utm_source=rss&utm_medium=rss&utm_campaign=here-we-go-again-lillys-alzheimers-drug-solanezumab-fails-to-show-efficacy-in-phase-3-but-company-is-encouraged-by-secondary-analysis Consulting for Effective Life R & D and Partnering Wed, 14 Nov 2018 00:20:29 +0000 hourly 1 https://wordpress.org/?v=6.9.4